Literature DB >> 12171882

Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry.

Lisa H Cazares1, Bao-Ling Adam, Michael D Ward, Suhail Nasim, Paul F Schellhammer, O John Semmes, George L Wright.   

Abstract

PURPOSE: The objective of this study was to discover protein biomarkers that differentiate malignant from nonmalignant cell populations, especially early protein alterations that signal the initiation of a developing cancer. We hypothesized that Surface Enhanced Laser Desorption/Ionization-time of flight-mass spectrometry-assisted protein profiling could detect these protein alterations. EXPERIMENTAL
DESIGN: Epithelial cell populations [benign prostatic hyperplasia (BPH), prostate intraepithelial neoplasia (PIN), and prostate cancer (PCA)] were procured from nine prostatectomy specimens using laser capture microdissection. Surface Enhanced Laser Desorption/Ionization-time of flight-mass spectrometry analysis was performed on cell lysates, and the relative intensity levels of each protein or peptide in the mass spectra was calculated and compared for each cell type.
RESULTS: Several small molecular mass peptides or proteins (3000-5000 Da) were found in greater abundance in PIN and PCA cell lysates. Another peak, with an average mass of 5666 Da, was observed to be up-regulated in 86% of the BPH cell lysates. Higher levels of this same peak were found in only 22% of the PIN lysates and none of the PCA lysates. Expression differences were also found for intracellular levels of prostate-specific antigen, which were reduced in PIN and PCA cells when compared with matched normals. Although no single protein alteration was observed in all PIN/PCA samples, combining two or more of the markers was effective in distinguishing the benign cell types (normal/BPH) from diseased cell types (PIN/PCA). Logistic regression analysis using seven differentially expressed proteins resulted in a predictive equation that correctly distinguished the diseased lysates with a sensitivity and specificity of 93.3 and 93.8%, respectively.
CONCLUSIONS: We have shown that the protein profiles from prostate cells with different disease states have discriminating differences. These differentially regulated proteins are potential markers for early detection and/or risk factors for development of prostate cancer. Studies are under way to identify these protein/peptides, with the goal of developing a diagnostic test for the early detection of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12171882

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  35 in total

Review 1.  Prostate cancer detection strategies.

Authors:  Timothy C Brand; Javier Hernandez; Edith D Canby-Hagino; Joseph W Basler; Ian M Thompson
Journal:  Curr Urol Rep       Date:  2006-05       Impact factor: 3.092

Review 2.  Clinical applications of proteomics: proteomic pattern diagnostics.

Authors:  Emanuel E Petricoin; Cloud P Paweletz; Lance A Liotta
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-10       Impact factor: 2.673

3.  Depicting the spatial distribution of proteins in human tumor tissue combining SELDI and MALDI imaging and immunohistochemistry.

Authors:  Liane Wehder; Günther Ernst; Anna C Crecelius; Orlando Guntinas-Lichius; Christian Melle; Ulrich S Schubert; Ferdinand von Eggeling
Journal:  J Histochem Cytochem       Date:  2010-07-19       Impact factor: 2.479

4.  Resampling and deconvolution of linear time-of-flight records for enhanced protein profiling.

Authors:  Dariya I Malyarenko; William E Cooke; Eugene R Tracy; Richard R Drake; Susanna Shin; O John Semmes; Maciek Sasinowski; Dennis M Manos
Journal:  Rapid Commun Mass Spectrom       Date:  2006       Impact factor: 2.419

5.  Modern Tumor Marker Discovery in Urology: Surface Enhanced Laser Desorption and Ionization (SELDI).

Authors:  Matthew B Gretzer; Alan W Partin; Daniel W Chan; Robert W Veltri
Journal:  Rev Urol       Date:  2003

6.  Optimization of MALDI-TOF MS detection for enhanced sensitivity of affinity-captured proteins spanning a 100 kDa mass range.

Authors:  Christine L Gatlin-Bunai; Lisa H Cazares; William E Cooke; Oliver J Semmes; Dariya I Malyarenko
Journal:  J Proteome Res       Date:  2007-10-05       Impact factor: 4.466

7.  SELDI-TOF MS profiling of serum for detection of laryngeal squamous cell carcinoma and the progression to lymph node metastasis.

Authors:  Lei Cheng; Liang Zhou; Lei Tao; Ming Zhang; Jiefeng Cui; Yan Li
Journal:  J Cancer Res Clin Oncol       Date:  2008-01-17       Impact factor: 4.553

8.  Preliminary study on proteomics of gastric carcinoma and its clinical significance.

Authors:  Hong-Gang Qian; Jing Shen; Hong Ma; Hua-Chong Ma; Ya-Hui Su; Chun-Yi Hao; Bao-Cai Xing; Xin-Fu Huang; Cheng-Chao Shou
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

9.  Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS.

Authors:  Melinda E Sanders; Eduardo C Dias; Baogang J Xu; James A Mobley; Dean Billheimer; Heinrich Roder; Julia Grigorieva; Mitchell Dowsett; Carlos L Arteaga; Richard M Caprioli
Journal:  J Proteome Res       Date:  2008-04-04       Impact factor: 4.466

Review 10.  Application and implementation of selective tissue microdissection and proteomic profiling in neurological disease.

Authors:  Jay Jagannathan; Jie Li; Nicholas Szerlip; Alexander O Vortmeyer; Russell R Lonser; Edward H Oldfield; Zhengping Zhuang
Journal:  Neurosurgery       Date:  2009-01       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.